IN2012DN01209A - - Google Patents
Info
- Publication number
- IN2012DN01209A IN2012DN01209A IN1209DEN2012A IN2012DN01209A IN 2012DN01209 A IN2012DN01209 A IN 2012DN01209A IN 1209DEN2012 A IN1209DEN2012 A IN 1209DEN2012A IN 2012DN01209 A IN2012DN01209 A IN 2012DN01209A
- Authority
- IN
- India
- Prior art keywords
- composition
- disclosed
- treating
- disorders
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22642509P | 2009-07-17 | 2009-07-17 | |
| PCT/US2010/042308 WO2011009061A1 (en) | 2009-07-17 | 2010-07-16 | Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01209A true IN2012DN01209A (ar) | 2015-04-10 |
Family
ID=42990151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1209DEN2012 IN2012DN01209A (ar) | 2009-07-17 | 2010-07-16 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110015179A1 (ar) |
| EP (1) | EP2453890B1 (ar) |
| JP (1) | JP2012533566A (ar) |
| KR (1) | KR101757003B1 (ar) |
| CN (1) | CN102497861A (ar) |
| AU (1) | AU2010273977A1 (ar) |
| BR (1) | BR112012001047A2 (ar) |
| CA (1) | CA2768356A1 (ar) |
| DK (1) | DK2453890T3 (ar) |
| ES (1) | ES2809298T3 (ar) |
| IN (1) | IN2012DN01209A (ar) |
| PT (1) | PT2453890T (ar) |
| RU (2) | RU2607946C2 (ar) |
| WO (1) | WO2011009061A1 (ar) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas blancharjq | ||
| US4166452A (en) * | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5409948A (en) * | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| US20050222123A1 (en) | 2004-01-27 | 2005-10-06 | North Shore-Long Island Jewish Research Institute | Cholinesterase inhibitors for treating inflammation |
| US20070212253A1 (en) * | 2004-12-21 | 2007-09-13 | Elrod Scott A | Descenting systems and methods |
| CN101151248B (zh) | 2005-01-26 | 2012-06-20 | 阿勒根公司 | 具有镇痛活性和/或免疫刺激物活性的3-芳基-3-羟基-2-氨基丙酸酰胺类、3-杂芳基-3-羟基-2-氨基丙酸酰胺类以及相关化合物 |
| CA2616858A1 (en) * | 2005-07-27 | 2007-02-01 | Carlos Henrique Horta Lima | Pharmaceutical preparation containing an acetylcholinesterase ihibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties. |
| EP1928437A2 (en) * | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| US20100105687A1 (en) * | 2007-03-06 | 2010-04-29 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
| WO2008109287A1 (en) | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| US8623891B2 (en) * | 2007-03-06 | 2014-01-07 | Allergan, Inc. | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| US8173683B2 (en) * | 2007-03-06 | 2012-05-08 | Allergan, Inc. | Methods for treating cognitive disorders |
| WO2009012082A1 (en) * | 2007-07-17 | 2009-01-22 | Allergan, Inc. | Methods for treating anxiety |
-
2010
- 2010-07-16 ES ES10735143T patent/ES2809298T3/es active Active
- 2010-07-16 US US12/838,019 patent/US20110015179A1/en not_active Abandoned
- 2010-07-16 CA CA2768356A patent/CA2768356A1/en not_active Abandoned
- 2010-07-16 WO PCT/US2010/042308 patent/WO2011009061A1/en active Application Filing
- 2010-07-16 PT PT107351439T patent/PT2453890T/pt unknown
- 2010-07-16 BR BR112012001047A patent/BR112012001047A2/pt not_active IP Right Cessation
- 2010-07-16 DK DK10735143.9T patent/DK2453890T3/da active
- 2010-07-16 JP JP2012520814A patent/JP2012533566A/ja active Pending
- 2010-07-16 AU AU2010273977A patent/AU2010273977A1/en not_active Abandoned
- 2010-07-16 EP EP10735143.9A patent/EP2453890B1/en active Active
- 2010-07-16 CN CN201080041187XA patent/CN102497861A/zh active Pending
- 2010-07-16 RU RU2012103401A patent/RU2607946C2/ru not_active Application Discontinuation
- 2010-07-16 RU RU2016151986A patent/RU2016151986A/ru not_active Application Discontinuation
- 2010-07-16 IN IN1209DEN2012 patent/IN2012DN01209A/en unknown
- 2010-07-16 KR KR1020127003979A patent/KR101757003B1/ko active IP Right Grant
-
2012
- 2012-10-11 US US13/649,404 patent/US9492543B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012001047A2 (pt) | 2019-09-24 |
| KR20120090029A (ko) | 2012-08-16 |
| KR101757003B1 (ko) | 2017-07-11 |
| EP2453890B1 (en) | 2020-05-27 |
| RU2016151986A (ru) | 2018-12-19 |
| JP2012533566A (ja) | 2012-12-27 |
| EP2453890A1 (en) | 2012-05-23 |
| RU2607946C2 (ru) | 2017-01-11 |
| RU2012103401A (ru) | 2013-08-27 |
| US9492543B2 (en) | 2016-11-15 |
| CA2768356A1 (en) | 2011-01-20 |
| US20110015179A1 (en) | 2011-01-20 |
| AU2010273977A1 (en) | 2012-02-02 |
| DK2453890T3 (da) | 2020-08-17 |
| PT2453890T (pt) | 2020-08-25 |
| US20130040938A1 (en) | 2013-02-14 |
| WO2011009061A1 (en) | 2011-01-20 |
| ES2809298T3 (es) | 2021-03-03 |
| CN102497861A (zh) | 2012-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG190819A1 (en) | Nampt and rock inhibitors | |
| EP4219465A3 (en) | Prmt5 inhibitors and uses thereof | |
| IN2012DN03883A (ar) | ||
| JO2892B1 (ar) | مثبطات cyp 17 | |
| EA201200373A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| MX2012004780A (es) | Inhibidores de akt. | |
| MY152271A (en) | Novel compounds that are erk inhibitors | |
| MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| JO3131B1 (ar) | مركبات كيميائية | |
| UA104885C2 (uk) | Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів | |
| MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
| MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
| GEP20125708B (en) | Hydroxamate-based inhibitors of deacetylases b | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| IN2012DN01273A (ar) | ||
| AU2011326186A8 (en) | Selective glycosidase inhibitors and uses thereof | |
| IN2012DN03182A (ar) | ||
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| MX2013002851A (es) | Inhibidores de tonum pectinacetilesterasa y metodos de su uso. | |
| PH12015500712A1 (en) | Azaquinazoline carboxamide derivatives | |
| WO2011088160A3 (en) | Novel cyp17 inhibitors | |
| IN2012DN03846A (ar) | ||
| WO2010077730A3 (en) | Indanone inhibitors of acetylcholinesterase |